Research And Grants

A Phase 1a Open-label Study Evaluating the Safety of 177Lu-DTPA-omburtamab delivered by CED in non-progressive DMG patients previously treated with external beam radiation therapy

DMG is a rare but aggressive brain tumor that primarily affects children. Despite advances in cancer treatment, DMG remains universally fatal, with most children surviving less than a year after diagnosis. One major challenge is that most drugs can't reach the tumor because of the brain’s natural defense system- the blood-brain barrier.

This study will test a new way to treat DMG using targeted radioactive antibody called 177Lu-DTPA-omburtamab, which attaches to a protein (B7-H3) found exclusively on tumor cells. To overcome the drug delivery challenge, we use a method called convection-enhanced delivery (CED), which involves delivering the drug directly into the tumor through a small tube placed in the brain. This allows for higher drug levels at the tumor site and less exposure to the rest of the body.

We are building on promising safety results from a previous first-in-human trial from our group utilizing CED delivery of radiolabeled omburtamab and will use that data to accelerate this new study. The goal is to determine how to safely give repeat doses. If successful, this treatment could offer new hope for children with DMG and pave the way for other targeted therapies.